Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Patent metadata

Field	Value
Publication number	US-12090147-B2
Application number	US-202017089359-A
Country	US
Kind code	B2
Filing date	Nov 4, 2020
Priority date	Nov 5, 2019
Publication date	Sep 17, 2024
Grant date	Sep 17, 2024

Abstract

Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1β blocker.

First claim

What is claimed:

1. A method of suppressing interleukin-10 induction related to 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, or clathrate thereof (Compound 1) in an acute myeloid leukemia patient, wherein the method comprises administering to the patient a therapeutically effective amount of Compound 1 and a therapeutically effective amount of second agent selected from prednisone, prednisolone, methylprednisolone, cortisol, cortisone, triamcinolone, betamethasone and dexamethasone.

2. The method of claim 1 , wherein the second agent is dexamethasone.

3. The method of claim 1 , wherein the interleukin-10 induction is suppressed by about 10% to 90%.

4. The method of claim 1 , wherein the therapeutically effective amount of Compound 1 is about 0.1 mg to about 10 mg.

5. The method of claim 1 , wherein the therapeutically effective amount of Compound 1 is about 0.3 mg, 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg, 3.6 mg, 4.5 mg, 5.4 mg or 8.1 mg per day.

6. The method of claim 1 , wherein Compound 1 is administered on days 1 to 5 of a 28 day treatment cycle.

7. The method of claim 6 , wherein the treatment cycle comprises a rest period of 23 days.

8. The method of claim 1 , wherein Compound 1 is administered on days 1 to 5 of a 42 day treatment cycle.

9. The method of claim 1 , wherein Compound 1 is administered on days 1 to 3 of a 28 day treatment cycle.

10. The method of claim 1 , wherein Compound 1 is administered on days 1 to 5 and days 15 to 19 of a 28 day treatment cycle.

11. The method of claim 6 , wherein the treatment cycle is repeated at least once.

12. The method of claim 11 , wherein the treatment cycle is repeated 2 to 4 times.

13. The method of claim 1 , wherein the method comprises administering one or more of calcium, calcitriol, or vitamin D supplementation.

14. The method of claim 1 , wherein the method comprises administering one or more of calcium, calcitriol, or vitamin D supplementation prior to Compound 1.

15. The method of claim 1 , wherein the method comprises administering one or more of calcium, calcitriol, or vitamin D supplementation at least 3 days prior to Compound 1 on day 1 of the cycle.

16. The method of claim 13 , wherein the patient does not have a disorder disrupting normal calcium homeostasis or preventing calcium supplementation.

17. The method of claim 1 , further comprising administering a therapeutically effective amount of another additional active agent or a supportive care therapy.

18. The method of claim 17 , wherein the additional active agent is selected from a hematopoietic growth factor, a cytokine, anti-cancer agent, an antibiotic, a cox-2 inhibitor, an immunomodulatory agent, an immunosuppressive agent, a corticosteroid or a pharmacologically active mutant or derivative thereof and a therapeutic antibody that specifically binds to a cancer antigen.

Assignees

• Celgene Corp

Inventors

• Buchholz Tonia
• Fan Jinhong
• Pierce Daniel W
• Pourdehnad Michael
• Yao Tsun-Wen

Classifications

• C07D401/14

  containing three or more hetero rings · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61K31/4545

  containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K31/047 Primary

  having two or more hydroxy groups, e.g. sorbitol · CPC title